172 results on '"Gianni, L"'
Search Results
2. P120 Cardiac safety of pertuzumab, trastuzumab and standard chemotherapy as neoadjuvant treatment for HER2 positive breast cancer: real world data from NeoPowER trial
3. Neoadjuvant immunotherapy in triple-negative breast cancer: lesson learnt, remaining questions
4. 216MO A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs weekly paclitaxel (P) as first- or second-line treatment in patients (pts) with ER+/HER2- metastatic breast cancer (MBC): The METEORA-II trial (IBCSG 54-16)
5. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
6. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
7. 257P Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
8. LBA12 Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial
9. 138P Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab + trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC)
10. 141P Gene-expression pathways and dynamics during neoadjuvant chemo-free therapy predict pathologic complete response in ER+/HER2+ breast cancer (BC)
11. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
12. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial
13. 42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)
14. LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial
15. LBA17 ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)
16. The Bipolar Prodrome: Meta-Analysis of Symptom Prevalence Prior to Initial or Recurrent Mood Episodes
17. The role of environmental exposures as risk factors for bipolar disorder: A systematic review of longitudinal studies
18. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study
19. Association of derived neutrophil-to-lymphocyte ratio (dNLR) with pathological complete response (pCR) after neoadjuvant chemotherapy (CT)
20. Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers
21. Correction to: Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
22. Time to CA19.9 nadir: a clue for defining treatment duration of primary chemotherapy in resectable PDAC
23. EP-1459 Impact of sentinel lymph-node biopsy and FDG-PET in staging and radiation treatment of anal cancer
24. Features preceding diagnosis of bipolar versus major depressive disorders
25. Clinical risk factors for bipolar disorders: A systematic review of prospective studies
26. PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)
27. Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial
28. Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies
29. The GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors
30. Role of immunotherapy (I) for advanced, pre-treated, non-squamous NSCLC (APNS-NSCLC): Preliminary data of a pooled analysis with network meta-analysis
31. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
32. A randomized phase II trial on neoadjuvant chemotherapy in resectable pancreatic adenocarcinoma
33. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoSphere study
34. PC.01.6 A MULTIDISCIPLINARY APPROACH TO FAMILIAL PANCREATIC CANCER ENRICHES THE PROPORTION OF PATIENTS WITH GENETICALLY CONFIRMED PANCREATIC CANCER SUSCEPTIBILITY
35. OC.13.1 ASSOCIATION OF GERMLINE GENE MUTATIONS IN EARLY ONSET GASTROINTESTINAL CANCERS WITH NEGATIVE FAMILY HISTORY
36. Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: A review
37. Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder/fear of harm phenotype
38. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma
39. Randomized phase 2 trial of peri- or post-operative chemotherapy in resectable pancreatic adenocarcinoma
40. Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (paxg regimen) in metastatic pancreatic adenocarcinoma
41. Everolimus-exemestane (EE) vs palbociclib-letrozole (PL) or palbociclib-fulvestrant (PF) in the treatment of metastatic HR+, HER2- breast cancer. Indirect comparisons with network meta-analysis for daily clinical practice
42. Everolimus-exemestane (EE) vs palbociclib-letrozole (PL) or palbociclib-fulvestrant (PF) in the treatment of metastatic HR+, HER2- breast cancer. An indirect comparison with network meta-analysis
43. Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in metastatic pancreatic adenocarcinoma
44. PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2-positive metastatic breast cancer
45. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
46. Treatment-emergent mania in pediatric bipolar disorder: a retrospective case review
47. Phase 1 study of first-in-class dUTPase inhibitor, TAS-114 in combination with S-1 in patients with advanced solid tumors
48. 136TiP IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC
49. Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trial
50. Correlations for tested doses and toxicities between first-in-human trials and registration trials of FDA-approved monoclonal antibodies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.